| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $495K | — | -4.3% |
| Cost of Revenue | $2.0M | — | +1286.4% |
| R&D Expense | $19.5M | — | +26.2% |
| SG&A Expense | $7.9M | — | -2.5% |
| Operating Income | -$28.9M | — | -24.8% |
| Income Tax | $0 | — | — |
| Net Income | -$17.6M | — | -145.0% |
| EPS (Basic) | -$0.09 | — | -132.1% |
| EPS (Diluted) | -$0.09 | — | -132.1% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $48.5M | -3.9% | -22.8% |
| Accounts Receivable | $434K | -1.6% | -11.1% |
| Inventory | $9.9M | -27.0% | +23.7% |
| Current Assets | $63.6M | -6.2% | -13.7% |
| Total Assets | $110.6M | -5.0% | -32.0% |
| Current Liabilities | $16.2M | -11.9% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$25.1M | — | +12.2% |
| Capital Expenditures | $175K | — | -23.2% |
| Investing Cash Flow | -$175K | — | +23.2% |
| Financing Cash Flow | $23.3M | — | -50.1% |
| Free Cash Flow | -$25.3M | — | +12.3% |
| -19.2% |
| Long-term Debt | $35.9M | +1.2% | — |
| Total Liabilities | $98.9M | -12.6% | -21.8% |
| Stockholders' Equity | $11.6M | +273.9% | -67.7% |